Evidence map›Paper›PMID 36060017›Full record

ArticleCancer diagnosis & prognosis

Oligometastatic Lymph Node Recurrence Detected Using

Shunsuke Mori, Taigo Kato, Tadashi Watabe, Koji Hatano, Toyohumi Abe, Shinichiro Fukuhara, Hiroshi Kiuchi, Ryoichi Imamura, Motohide Uemura, Norio Nonomura

Abstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancer diagnosis & prognosis. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Recurrent Prostate Cancer Diagnostics withDiagnostics (Basel, Switzerland) · 2022
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Shunsuke MoriDepartment of Urology, Osaka University Graduate School of Medicine, Osaka, Japan.
Taigo KatoDepartment of Urology, Osaka University Graduate School of Medicine, Osaka, Japan.
Tadashi WatabeDepartment of Nuclear Medicine and Tracer Kinetics, Osaka University Graduate School of Medicine, Osaka, Japan.
Koji HatanoDepartment of Urology, Osaka University Graduate School of Medicine, Osaka, Japan.
Toyohumi AbeDepartment of Urology, Osaka University Graduate School of Medicine, Osaka, Japan.
Shinichiro FukuharaDepartment of Urology, Osaka University Graduate School of Medicine, Osaka, Japan.
Hiroshi KiuchiDepartment of Urology, Osaka University Graduate School of Medicine, Osaka, Japan.
Ryoichi ImamuraDepartment of Urology, Osaka University Graduate School of Medicine, Osaka, Japan.
Motohide UemuraDepartment of Urology, Osaka University Graduate School of Medicine, Osaka, Japan.
Norio NonomuraDepartment of Urology, Osaka University Graduate School of Medicine, Osaka, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

BACKGROUND/

aimProstate cancer (PC) is one of the most common types of cancer in men worldwide. Most patients with metastatic PC are treated with androgen deprivation therapy (ADT) using luteinizing hormone-releasing hormone agonists and antagonists as first-line therapy. The majority of PC patients develop a castration-resistant PC (CRPC), which eventually leads to high mortality with poor prognosis, despite new targeted therapies. However, given that oligometastatic recurrence may enable local therapy in CRPC, accurate detection of metastatic lesions may improve clinical outcomes in patients with CRPC. CASE REPORT: We report the case of an 83-year-old man with CRPC.

conclusionThis study indicates a novel approach to oligometastatic CRPC by means of accurate staging with

Indexed as

castration-resistant prostate canceroligometastatic lymph node recurrenceProstate cancer

Identifiers

PMID36060017
PMCPMC9425584

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.